This review explores recent advancements in gerobiotics research, focusing on their role in targeting aging hallmarks, regulating longevity-associated pathways, and reducing risks of multiple age-related chronic conditions
Adherence at twelve months is much lower than the headline numbers suggest, and rebound weight regain in the year after discontinuation is now well-documented enough to be the basis of a new clinical category, chronic GLP-1 maintenance therapy, with all the lifelong-medication implications that phrase implies
The GLP-1 RAs appear to modify atherosclerosis in the arteries, much like statin medications that treat cholesterol, and takes about a year or more to demonstrate measurable benefits on risk for cardiovascular events, whereas the SGLT2i medications seem to affect heart and kidney function more prominently and faster, with benefits evident very soon after starting the medication
The two weight management basket trials (TRIUMPH-1 and TRIUMPH-2) with OSA and/or OA protocols nested within the weight management trial
All references are limited to controlled laboratory research environments
Why is consistency important for weight control
